MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Investigating inflammatory mechanisms in iPSC-derived LRRK2 microglia

K. Badanjak, P. Mulica, P. Seibler, M. Ali, C. Venegas, S. Pereira, C. Klein, P. Antony, E. Glaab, A. Grünewald (Esch-Sur-Alzette, Luxembourg)

Meeting: 2022 International Congress

Abstract Number: 1352

Keywords: Inflammation, Microglia, Parkinson’s

Category: Parkinson's Disease: Molecular Mechanisms of Disease

Objective: To characterize microglial function and inflammatory mechanisms in LRRK2-associated Parkinson’s disease (PD).

Background: PD is a neurodegenerative disease affecting primarily dopaminergic neurons of the substantia nigra pars compacta. Mutations in LRRK2 cause the most frequent genetic form of PD. While neuronal phenotypes are commonly being investigated in the context of LRRK2-PD, inflammatory processes and the activation of microglia have also been described in different disease models.

Method: We used an established differentiation protocol to derive microglia from iPSCs of affected and unaffected LRRK2 G2019S mutation carriers as well as healthy and isogenic controls. To trigger an inflammatory response, the cultures were exposed to the cytokine interferon gamma (IFN-γ). Before and after treatment, we assessed the LRRK2 phosphorylation status by means of Western blotting, performed immunocytochemistry of PD-specific targets, and subjected the cultures to RNA sequencing to evaluate differentially expressed genes and pathways.

Results: LRRK2 G2019S microglia display higher levels of phosphorylation at serine 1292 (S1292) upon IFN-γ treatment compared to healthy control and gene-corrected cells, suggestive of increased LRRK2 kinase activity upon inflammatory stimuli in mutant cells. We were able to rescue this phenotype by treating G2019S-mutant microglia with MLi-2 – a potent LRRK2 kinase inhibitor. In addition, we found significantly higher levels of α-synuclein in microglia derived from manifesting PD patients after stimulation with IFN-γ compared to, both, microglia from non-manifesting G2019S mutation carriers and gene-corrected control cells, providing insights into mechanisms of disease manifestation. Finally, our RNAseq dataset revealed proinflammatory signaling in LRRK2-mutant microglia.

Conclusion: Upon inflammatory stimulus, S1292-LRRK2 is a mutation-specific marker of LRRK2 kinase activity, while endogenous levels of microglial α-synuclein pose a possible mechanism of disease manifestation in our iPSC-derived microglia models. Our data highlights microglia as significant contributors to the pathogenesis of LRRK2-PD.

To cite this abstract in AMA style:

K. Badanjak, P. Mulica, P. Seibler, M. Ali, C. Venegas, S. Pereira, C. Klein, P. Antony, E. Glaab, A. Grünewald. Investigating inflammatory mechanisms in iPSC-derived LRRK2 microglia [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/investigating-inflammatory-mechanisms-in-ipsc-derived-lrrk2-microglia/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/investigating-inflammatory-mechanisms-in-ipsc-derived-lrrk2-microglia/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley